Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia

This trial is testing NK520 — a natural killer (NK) cell therapy — for adults with relapsed or refractory acute myeloid leukemia (AML) that has not responded to or has come back after at least 2 lines of treatment. It is the adult version of a similar pediatric trial testing the same therapy. **You may be eligible if...** - You are 18–75 years old with a confirmed diagnosis of AML - Your leukemia has relapsed or is refractory (not responding to treatment) after at least 2 prior treatment regimens - You are not a candidate for other currently available therapies **You may NOT be eligible if...** - You are younger than 18 or older than 75 - Your diagnosis does not meet WHO criteria for AML - You have serious organ dysfunction or other conditions preventing safe participation Talk to your doctor to see if this trial is right for you.